Geneva Capital Management LLC Has $81.54 Million Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Geneva Capital Management LLC trimmed its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.2% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 877,845 shares of the medical instruments supplier’s stock after selling 1,682 shares during the quarter. LeMaitre Vascular accounts for 1.4% of Geneva Capital Management LLC’s holdings, making the stock its 24th biggest position. Geneva Capital Management LLC owned approximately 3.91% of LeMaitre Vascular worth $81,543,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. CANADA LIFE ASSURANCE Co lifted its position in LeMaitre Vascular by 44.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after acquiring an additional 6,875 shares in the last quarter. Quantbot Technologies LP boosted its position in shares of LeMaitre Vascular by 1,001.4% during the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock worth $487,000 after buying an additional 6,669 shares during the period. Quadrature Capital Ltd grew its holdings in shares of LeMaitre Vascular by 129.4% during the first quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock worth $1,484,000 after buying an additional 12,654 shares in the last quarter. Janus Henderson Group PLC raised its position in LeMaitre Vascular by 554.7% in the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock valued at $3,697,000 after buying an additional 47,218 shares during the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in LeMaitre Vascular in the 2nd quarter valued at approximately $1,010,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $103.26 on Wednesday. The firm’s fifty day moving average price is $90.96 and its two-hundred day moving average price is $84.86. The company has a market cap of $2.32 billion, a P/E ratio of 56.43, a P/E/G ratio of 2.58 and a beta of 0.89. LeMaitre Vascular, Inc. has a one year low of $48.66 and a one year high of $106.49.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same period in the previous year, the company posted $0.33 EPS. The firm’s quarterly revenue was up 15.6% on a year-over-year basis. As a group, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on LMAT shares. Lake Street Capital started coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective on the stock. Oppenheimer reissued an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research increased their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price on the stock. Finally, StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.